
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
An exciting industry consisting of companies who develop new drugs to combat such diseases as cancer and other life-threatening diseases. Some may also participate in gene therapy. These firms either bring new drugs to the market themselves (which is a grueling process) or they sell their technology to bigger pharmaceutical companies.
|
Totals |
Company |
Industry |
Sales: |
N/A |
$86,114.6 Mil |
Market Cap: |
$20.2 Mil |
$486,078.3 Mil |
Analysts Recommendation: |
Strong Buy |
Buy |
|
|
Averages |
Company |
Industry |
 |
Growth |
Historic Revenue: |
N/A |
54.4% |
Estimated Revenue: |
N/A |
5.5% |
Historic Earnings: |
N/A |
13.0% |
Estimated Earnings: |
N/A |
7.7% |
Stock Price (1 Year): |
(61.8%) |
19.2% |
Cash per Share: |
N/A |
144.2% |
Dividend: |
N/A |
N/A |
Price |
Trailing PE: |
N/A |
N/A |
Forward PE: |
N/A |
40.1 |
Price-to-Sales: |
N/A |
N/A |
Price-to-Book: |
N/A |
5.7 |
Dividend Yield: |
N/A |
N/A |
Market Cap: |
$20.2 Mil |
$10,801.7 Mil |
Operations |
Net Margin: |
N/A |
(624.2%) |
Gross Margin: |
N/A |
83.4% |
Return on Equity: |
N/A |
.2 |
Return on Assets: |
N/A |
(.0) |
Balance Sheet |
Current Ratio: |
N/A |
3.1 |
Quick Ratio: |
N/A |
2.7 |
Cash Ratio: |
N/A |
1.9 |
Debt-to-Equity: |
N/A |
1.2 |
Interest Coverage: |
N/A |
.4 |
Technicals |
Relative-Strength Index: |
N/A |
46.1 |
|
|
|